Cooley LLP announced today that it advised Flexion Therapeutics on its $74.8 million IPO. Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company now trades on the NASDAQ Global Market under the symbol “FLXN.”
The Cooley corporate and securities team that advised Flexion included partners Tom Coll, Marc Recht and Sean Clayton, as well as associates Rob Hadfield, Jon Russo, Scott Tanner, Terren O’Connor, Anna Jarosinski, Dani Nazemian and Jessica Wade. Critical Support for the offering was provided by partner Natasha Leskovsek (regulatory); associate Megan Arthur (compensation &
